

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **ANNOUNCEMENT**

### **PRINCIPAL FINANCIAL INFORMATION OF CR DOUBLE-CRANE FOR THE YEAR ENDED 31 DECEMBER 2022**

On 27 March 2023, CR Double-Crane released its annual report for the year ended 31 December 2022.

China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) (“**CR Double-Crane**”) is a company incorporated in the People’s Republic of China. The shares of CR Double-Crane are listed on the Shanghai Stock Exchange. As of the date of this announcement, CR Double-Crane is indirectly owned as to 59.99% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 27 March 2023, CR Double-Crane released its annual report for the year ended 31 December 2022 (the “**CR Double-Crane Audited Annual Financials**”). Set out below are the key financial information of the CR Double-Crane Audited Annual Financials:

	As of 31 December 2022 <i>(RMB)</i> <b>(audited)</b>	As of 31 December 2021 <i>(RMB)</i> <b>(audited)</b>	<b>Increase</b> <i>(%)</i>
Total assets	<b>14,482,536,656.83</b>	13,676,050,322.84	5.90%
Net assets attributable to shareholders of the listed company	<b>10,022,611,149.67</b>	9,905,495,654.72	1.18%
	For the year ended 31 December		
	2022 <i>(RMB)</i> <b>(audited)</b>	2021 <i>(RMB)</i> <b>(audited)</b>	<b>Increase</b> <i>(%)</i>
Revenue	<b>9,446,925,267.13</b>	9,111,516,930.74	3.68%
Net profit attributable to the shareholders of the listed company	<b>1,163,649,615.44</b>	935,685,482.77	24.36%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	<b>1,088,710,800.45</b>	870,334,660.51	25.09%
Net cash flow from operating activities	<b>1,341,669,648.48</b>	1,340,920,963.61	0.06%
Basic earnings per share <i>(RMB/share)</i>	<b>1.1235</b>	0.8969	25.26%
Diluted earnings per share <i>(RMB/share)</i>	<b>1.1235</b>	0.8969	25.26%
Weighted average return on net asset <i>(%)</i>	<b>11.71%</b>	9.78%	1.93 percentage points

As determined by the board of directors of CR Double-Crane, CR Double-Crane proposed to distribute a cash dividend of RMB2.89 (inclusive of tax) for every 10 shares to all shareholders of CR Double-Crane based on the total share capital registered on the record date of equity distribution registration, shall be calculated by deducting the share in the repurchased special account at that time. Such proposal shall be submitted for shareholders’ approval at CR Double-Crane’s 2022 annual general meeting.

The CR Double-Crane Audited Annual Financials have been prepared and audited in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to CR Double-Crane only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Double-Crane Audited Annual Financials, please refer to the annual report for the year ended 31 December 2022 published by CR Double-Crane on the website of the Shanghai Stock Exchange ([www.sse.com.cn](http://www.sse.com.cn)).

By order of the Board of Directors  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Hong Kong, 28 March 2023

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*